Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CE-MS-based urinary biomarkers to distinguish non-significant from significant prostate cancer.
Frantzi M, Gomez Gomez E, Blanca Pedregosa A, Valero Rosa J, Latosinska A, Culig Z, Merseburger AS, Luque RM, Requena Tapia MJ, Mischak H, Carrasco Valiente J. Frantzi M, et al. Among authors: valero rosa j. Br J Cancer. 2019 Jun;120(12):1120-1128. doi: 10.1038/s41416-019-0472-z. Epub 2019 May 16. Br J Cancer. 2019. PMID: 31092909 Free PMC article.
Ghrelin O-acyltransferase (GOAT) enzyme is overexpressed in prostate cancer, and its levels are associated with patient's metabolic status: Potential value as a non-invasive biomarker.
Hormaechea-Agulla D, Gómez-Gómez E, Ibáñez-Costa A, Carrasco-Valiente J, Rivero-Cortés E, L-López F, Pedraza-Arevalo S, Valero-Rosa J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Gahete MD, López-Miranda J, Requena MJ, Castaño JP, Luque RM. Hormaechea-Agulla D, et al. Among authors: valero rosa j. Cancer Lett. 2016 Dec 1;383(1):125-134. doi: 10.1016/j.canlet.2016.09.022. Epub 2016 Sep 28. Cancer Lett. 2016. PMID: 27693462
The oncogenic role of the In1-ghrelin splicing variant in prostate cancer aggressiveness.
Hormaechea-Agulla D, Gahete MD, Jiménez-Vacas JM, Gómez-Gómez E, Ibáñez-Costa A, L-López F, Rivero-Cortés E, Sarmento-Cabral A, Valero-Rosa J, Carrasco-Valiente J, Sánchez-Sánchez R, Ortega-Salas R, Moreno MM, Tsomaia N, Swanson SM, Culler MD, Requena MJ, Castaño JP, Luque RM. Hormaechea-Agulla D, et al. Among authors: valero rosa j. Mol Cancer. 2017 Aug 29;16(1):146. doi: 10.1186/s12943-017-0713-9. Mol Cancer. 2017. PMID: 28851363 Free PMC article.
Plasma ghrelin O-acyltransferase (GOAT) enzyme levels: A novel non-invasive diagnosis tool for patients with significant prostate cancer.
Gómez-Gómez E, Jiménez-Vacas JM, Carrasco-Valiente J, Herrero-Aguayo V, Blanca-Pedregosa AM, León-González AJ, Valero-Rosa J, Fernández-Rueda JL, González-Serrano T, López-Miranda J, Gahete MD, Castaño JP, Requena-Tapia MJ, Luque RM. Gómez-Gómez E, et al. Among authors: valero rosa j. J Cell Mol Med. 2018 Nov;22(11):5688-5697. doi: 10.1111/jcmm.13845. Epub 2018 Sep 6. J Cell Mol Med. 2018. PMID: 30256519 Free PMC article.
Clinical association of metabolic syndrome, C-reactive protein and testosterone levels with clinically significant prostate cancer.
Gómez-Gómez E, Carrasco-Valiente J, Campos-Hernández JP, Blanca-Pedregosa AM, Jiménez-Vacas JM, Ruiz-García J, Valero-Rosa J, Luque RM, Requena-Tapia MJ. Gómez-Gómez E, et al. Among authors: valero rosa j. J Cell Mol Med. 2019 Feb;23(2):934-942. doi: 10.1111/jcmm.13994. Epub 2018 Nov 18. J Cell Mol Med. 2019. PMID: 30450757 Free PMC article.
Serum biomarkers for diagnosis and characterization of prostate cancer.
Gómez Gómez E, Puche Sanz I, Valero Rosa J, Carrasco Valiente J, Campos Hernandez JP, Anglada Curado FJ. Gómez Gómez E, et al. Among authors: valero rosa j. Arch Esp Urol. 2022 Mar;75(2):156-164. Arch Esp Urol. 2022. PMID: 35332885 Free article. Review. English, Spanish.
European Randomized Study of Screening for Prostate Cancer Risk Calculator: External Validation, Variability, and Clinical Significance.
Gómez-Gómez E, Carrasco-Valiente J, Blanca-Pedregosa A, Barco-Sánchez B, Fernandez-Rueda JL, Molina-Abril H, Valero-Rosa J, Font-Ugalde P, Requena-Tapia MJ. Gómez-Gómez E, et al. Among authors: valero rosa j. Urology. 2017 Apr;102:85-91. doi: 10.1016/j.urology.2016.11.004. Epub 2016 Nov 10. Urology. 2017. PMID: 27840252
New Approach to Guide Target Prostate Biopsy: Technique and Initial Experience.
Gómez Gómez E, Valero Rosa J, Carrasco Valiente J, Triviño Tarradas F, Anglada Curado F, López Ruiz D, Requena Tapia MJ. Gómez Gómez E, et al. Among authors: valero rosa j. Urology. 2018 Nov;121:198-199. doi: 10.1016/j.urology.2017.08.027. Epub 2017 Sep 4. Urology. 2018. PMID: 29074136
Oncogenic Role of Secreted Engrailed Homeobox 2 (EN2) in Prostate Cancer.
Gómez-Gómez E, Jiménez-Vacas JM, Pedraza-Arévalo S, López-López F, Herrero-Aguayo V, Hormaechea-Agulla D, Valero-Rosa J, Ibáñez-Costa A, León-González AJ, Sánchez-Sánchez R, González-Serrano T, Requena-Tapia MJ, Castaño JP, Carrasco-Valiente J, Gahete MD, Luque RM. Gómez-Gómez E, et al. Among authors: valero rosa j. J Clin Med. 2019 Sep 6;8(9):1400. doi: 10.3390/jcm8091400. J Clin Med. 2019. PMID: 31500112 Free PMC article.
Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.
Gomez Gomez E, Salamanca Bustos JJ, Carrasco Valiente J, Fernandez Rueda JL, Blanca A, Valero Rosa J, Bravo Arrebola I, Marquez López J, Jimenez Vacas JM, Luque R, Requena Tapia MJ. Gomez Gomez E, et al. Among authors: valero rosa j. BMJ Open. 2019 Nov 12;9(11):e031032. doi: 10.1136/bmjopen-2019-031032. BMJ Open. 2019. PMID: 31722940 Free PMC article.
21 results